Track topics on Twitter Track topics that are important to you
Bayer has announced that it has received European Commission approval for its treatment of hepatocellular carcinoma, a type of liver cancer, as second-line treatment. This means that Stivarga will be available to use after Bayer’s other therapy, Nexavar, used in first-line treatment.
The approval comes after the treatment had already been approved in the US and Japan for second-line treatment, in April and June respectively. The decision was based on the results from its RESORCE trial showed that the drug was able to improve overall survival (OS) in patients.
Original Article: Bayer secures one-two treatment for liver cancer after EU approvalNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...